Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy.

18 F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) allows to quantify the metabolic activity of a tumor (glycolysis) and has become a reference tool in oncology for the staging, restaging, radiotherapy planning and monitoring response in many cancers. Quantitative analyses have been introduced in order to overcome some of the limits of the visual methods, allowing an easier and more objective comparison of the inter- and intra-patients variations. The aims of this review were to report available evidences on the clinical value of quantitative PET/CT parameters in HNC. Forty-five studies, for a total of 2928 patients, were analyzed. Most of the data available dealt with the intensity of the metabolism, calculated from the Standard Uptake Value (SUV). Metabolic Tumor Volume (MTV) was well correlated with overall survival and disease free survival, with a higher predictive value than the maximum SUV. Spatial distribution of metabolism and textural analyses seems promising.

[1]  John P A Ioannidis,et al.  F-Fluorodeoxyglucose Positron Emission Tomography to Evaluate Cervical Node Metastases in Patients With Head and Neck Squamous Cell Carcinoma: A Meta-analysis , 2008 .

[2]  Dong-Wan Kim,et al.  Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study , 2016, BMC Cancer.

[3]  J. L. Lacau St Guily,et al.  Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database , 2010, Head & neck oncology.

[4]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[5]  Y. Nishiyama,et al.  Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. , 2009, Auris, nasus, larynx.

[6]  Robert M. Haralick,et al.  Textural Features for Image Classification , 1973, IEEE Trans. Syst. Man Cybern..

[7]  R. Boellaard,et al.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  A. Garden,et al.  Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[9]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[10]  R. D'Agostino,et al.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer , 2001, Head & neck.

[11]  Quynh-Thu Le,et al.  Metabolic tumor burden predicts for disease progression and death in lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[12]  Vincent Grégoire,et al.  Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Pignon,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer , 2001 .

[14]  Christopher U. Jones,et al.  Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. , 2015, International journal of radiation oncology, biology, physics.

[15]  Elisabeth Kjellén,et al.  FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head & neck.

[16]  T. Taguchi,et al.  Predictive and Prognostic Value of Metabolic Tumor Volume (MTV) in Patients with Laryngeal Carcinoma Treated by Radiotherapy (RT) / Concurrent Chemoradiotherapy (CCRT) , 2015, PloS one.

[17]  B. Loo,et al.  Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. , 2011, International journal of radiation oncology, biology, physics.

[18]  Ningyu Wang,et al.  18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis. , 2013, Surgical oncology.

[19]  Mark T Lee,et al.  Prognostic role of metabolic parameters of 18F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Ngan-Ming Tsang,et al.  Prognostic Significance of 18F-FDG PET Parameters and Plasma Epstein-Barr Virus DNA Load in Patients with Nasopharyngeal Carcinoma , 2012, The Journal of Nuclear Medicine.

[21]  J. Keyes.  SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[23]  R. Kloiber,et al.  Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: A prospective clinical trial , 2011, Head & neck.

[24]  M. Aznar,et al.  Prognostic value of 18F‐fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma , 2015, Head & neck.

[25]  I. Apostolova,et al.  Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Yuji Nakamoto,et al.  Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[27]  Y. Nishiyama,et al.  Early prediction of local control in head and neck cancer after chemoradiotherapy by FDG-PET , 2011, Nuclear medicine communications.

[28]  Dimitri Van De Ville,et al.  Three-dimensional solid texture analysis in biomedical imaging: Review and opportunities , 2014, Medical Image Anal..

[29]  Mark T Lee,et al.  18F‐FDG PET–CT performed before and during radiation therapy of head and neck squamous cell carcinoma: Are they independent or complementary to each other? , 2016, Journal of medical imaging and radiation oncology.

[30]  S. Yang,et al.  Risk Stratification of Metastatic Neck Nodes by CT and PET in Patients with Head and Neck Cancer Receiving Definitive Radiotherapy , 2015, The Journal of Nuclear Medicine.

[31]  D. Morgan.  Radiotherapy in head and neck cancer , 1997, The Journal of Laryngology & Otology.

[32]  Chun-Ta Liao,et al.  Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T-Stage Oropharyngeal Squamous Cell Carcinoma , 2013, The Journal of Nuclear Medicine.

[33]  P. Castaldi,et al.  Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  Brit B. Turnbull,et al.  Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. , 2008, International journal of radiation oncology, biology, physics.

[35]  Claude Nahmias,et al.  Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors , 2008, Journal of Nuclear Medicine.

[36]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[37]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[38]  F. Alongi,et al.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. , 2016, The British journal of radiology.

[39]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[40]  J. Manens,et al.  Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control , 2013, Radiation Oncology.

[41]  T. Turkington,et al.  Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. , 2012, International journal of radiation oncology, biology, physics.

[42]  Quynh-Thu Le,et al.  Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. , 2012, International journal of radiation oncology, biology, physics.

[43]  Chris R Chatwin,et al.  Three-Dimensional Selective-Scale Texture Analysis of Computed Tomography Pulmonary Angiograms , 2008, Investigative radiology.

[44]  J. Yoo,et al.  Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[45]  Paul N. Span,et al.  Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[46]  H. Ashamalla,et al.  The Anatomical Biological Value on Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography Computed Tomography Predicts Response and Survival in Locally Advanced Head and Neck Cancer , 2014, World journal of nuclear medicine.

[47]  S. Yang,et al.  Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  Mohamed Allaoua,et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  G. Storme,et al.  Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? , 2010, Nuclear medicine communications.

[50]  T. Taguchi,et al.  Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-d-glucose positron emission tomography. , 2008, Auris, nasus, larynx.

[51]  S. Yang,et al.  Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer , 2014, The Laryngoscope.

[52]  R. Reisman,et al.  I. Clinical response , 1981 .

[53]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  Martin A Lodge,et al.  Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer , 2005, Nuclear medicine communications.

[55]  N. Lee,et al.  The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan. , 2014, Oral oncology.

[56]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  R. Coleman,et al.  Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.

[58]  I. Apostolova,et al.  Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer , 2014, European Radiology.

[59]  N. Sadato,et al.  FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[60]  M. Baumann,et al.  Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  M. Matoba,et al.  Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT , 2015, Journal of radiation research.

[62]  Ching-Han Hsu,et al.  Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  K. Kamiya,et al.  Prognostic value of post-treatment (18)F-FDG PET/CT for advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy. , 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[64]  T. Hyslop,et al.  Pretreatment FDG‐PET standardized uptake value as a prognostic factor for outcome in head and neck cancer , 2009, Head & neck.

[65]  J. Thie.  Understanding the standardized uptake value, its methods, and implications for usage. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[66]  W. Wong,et al.  18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers--an audit and review of published studies. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).